Vaccination of macaques with attenuated SIV strains has consistently provided the most effective protection against pathogenic SIV challenge and offers the best available experimental model to define specific mechanisms responsible for protection. Recent studies from our group have demonstrated that a significant maturation of protective immunity against vaginal challenge occurs between 5 and 20 weeks after vaccination with SIVAnef, which is associated with evolution of both cellular and humoral immune responses. Furthermore, SIVAnef-vaccinated animals do not manifest the recently described mobilization of pDCs and recruitment of CD4+ T cells that occurs early after vaginal challenge of naive animals. Based on these observations, we hypothesize that SIVAnef is able to block critical stages of SIV replication and spread in the first 7 days after vaginal challenge. Since our previous studies have largely focused on later time points (>7 days after challenge) and examination of immune responses in the peripheral blood, these emerging data dictate a new and comprehensive analysis of the early events in tissues following vaginal challenge of SIVAnef-vaccinated animals. The goal of this proposal is to apply a panel of innovative techniques to serial necropsies of SIVAnef-vaccinated animals before and after challenge to elucidate the roles of adaptive and innate immune responses in mediating protection induced by SIVAnef and to identify the sites of containment of viral replication within the female reproductive tract.
Specific aims i nclude: 1: To examine the evolution of adaptive and innate immune responses in the female reproductive tract induced by SIVAnef;2. To identify sites of viral containment and characterize local immune responses following vaginal challenge of SIVAnef-vaccinated animals;and 3. To examine the effect of B cell depletion on protective immunity against vaginal challenge induced by SIVAnef. These studies will provide novel insights into mechanisms of protective immunity induced by SIVAnef, offer a direct comparison of both immunologic and virologic analyses for animals vaccinated with alternative vectors, and ultimately guide the identification of mechanisms of protection against mucosal infection with lentiviruses.
Lack of information on mechanisms of protective immunity against HIV remains one of the leading barriers to the development of a safe and effective AIDS vaccine. These studies will use a live attenuated SIV vaccine, which has provided the most consistent protection in monkey studies so far, to help identify the types of immune responses that should be induced by clinically applicable AIDS vaccines.
|Aid, Malika; Abbink, Peter; Larocca, Rafael A et al. (2017) Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. Cell 169:610-620.e14|
|Barouch, Dan H; Thomas, Stephen J; Michael, Nelson L (2017) Prospects for a Zika Virus Vaccine. Immunity 46:176-182|
|Abbink, Peter; Larocca, Rafael A; Visitsunthorn, Kittipos et al. (2017) Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Sci Transl Med 9:|
|Ackerman, Margaret E; Barouch, Dan H; Alter, Galit (2017) Systems serology for evaluation of HIV vaccine trials. Immunol Rev 275:262-270|
|McMichael, Andrew J; Picker, Louis J (2017) Unusual antigen presentation offers new insight into HIV vaccine design. Curr Opin Immunol 46:75-81|
|Keele, Brandon F; Li, Wenjun; Borducchi, Erica N et al. (2017) Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. Nat Commun 8:15740|
|Zeng, Ming; Smith, Anthony J; Shang, Liang et al. (2016) Mucosal Humoral Immune Response to SIVmac239?nef Vaccination and Vaginal Challenge. J Immunol 196:2809-18|
|Liu, Jinyan; Ghneim, Khader; Sok, Devin et al. (2016) Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. Science 353:1045-1049|
|Martinez-Navio, José M; Fuchs, Sebastian P; Pedreño-López, Sònia et al. (2016) Host Anti-antibody Responses Following Adeno-associated Virus-mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys. Mol Ther 24:76-86|
|Stephenson, Kathryn E; Neubauer, George H; Bricault, Christine A et al. (2016) Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy. Open Forum Infect Dis 3:ofw100|
Showing the most recent 10 out of 52 publications